Development of 6E3 antibody-mediated SERS immunoassay for drug-resistant influenza virus

Hyeran Kim, Hyunju Kang, Hye Nan Kim, Hongki Kim, Jeong Moon, Kyeonghye Guk, Hwangseo Park, Dongeun Yong, Pan Kee Bae, Hyun Gyu Park, Eun Kyung Lim, Taejoon Kang, Juyeon Jung

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Influenza viruses are responsible for several pandemics and seasonal epidemics and pose a major public health threat. Even after a major outbreak, the emergence of drug-resistant influenza viruses can pose disease control problems. Here we report a novel 6E3 monoclonal antibody capable of recognizing and binding to the H275Y neuraminidase (NA) mutation, which has been associated with reduced susceptibility of influenza viruses to NA inhibitors. The 6E3 antibody had a KD of 72.74 μM for wild-type NA and 32.76 pM for H275Y NA, suggesting that it can identify drug-resistant pandemic H1N1 (pH1N1) influenza virus. Molecular modeling studies also suggest the high-affinity binding of this antibody to pH1N1 H275Y NA. This antibody was also subject to dot-blot, enzyme-linked immunosorbent assay, bare-eye detection, and lateral flow assay to demonstrate its specificity to drug-resistant pH1N1. Furthermore, it was immobilized on Au nanoplate and nanoparticles, enabling surface-enhanced Raman scattering (SERS)-based detection of the H275Y mutant pH1N1. Using 6E3 antibody-mediated SERS immunoassay, the drug-resistant influenza virus can be detected at a low concentration of 102 plaque-forming units/mL. We also detected pH1N1 in human nasopharyngeal aspirate samples, suggesting that the 6E3-mediated SERS assay has the potential for diagnostic application. We anticipate that this newly developed antibody and SERS-based immunoassay will contribute to the diagnosis of drug-resistant influenza viruses and improve treatment strategies for influenza patients.

Original languageEnglish
Article number113324
JournalBiosensors and Bioelectronics
Publication statusPublished - 2021 Sept 1

Bibliographical note

Funding Information:
This research was supported by National R&D Programs through National Research Foundation (NRF) of Korea funded by Ministry of Science and ICT (MSIT) of Korea ( NRF-2019R1C1C1006867 , NRF-2021M3H4A1A02051048 , NRF-2018M3A9E2022821 , and NRF-2020R1A2C1010453 ), Global Frontier Program through Center for BioNano Health-Guard funded by MSIT of Korea ( H-GUARD_2013M3A6B2078950 and H-GUARD_2014M3A6B2060507 ), Technology Development Program for Biological Hazards Management in Indoor Air through Korea Environment Industry & Technology Institute (KEITI) funded by Ministry of Environment (ME) of Korea ( 2021003370003 ), Industrial Technology Alchemist Program of the Ministry of Trade, Industry, and Energy (MOTIE) of Korea ( 20012435 ), Nanomedical Devices Development Program of NNFC , and the KRIBB Research Initiative Program ( 1711134081 ).

Publisher Copyright:
© 2021 The Authors

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biophysics
  • Biomedical Engineering
  • Electrochemistry


Dive into the research topics of 'Development of 6E3 antibody-mediated SERS immunoassay for drug-resistant influenza virus'. Together they form a unique fingerprint.

Cite this